Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: A systematic review

Neurotoxicity Research

Volumn 22, Issue 4, 2012, Pages 265-273

  Colosimo, Carlo ^a   Tiple, Dorina ^a   Berardelli, Alfredo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Botulinum toxin; Dystonia; Long term treatment; Symptomatic therapy

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; TOXIN ANTIBODY;

ANTIBODY PRODUCTION; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL FEATURE; CRANIOCERVICAL DYSTONIA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPHAGIA; DYSTONIA; HOARSENESS; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; LONGITUDINAL STUDY; MUSCLE WEAKNESS; NECK PAIN; OROMANDIBULAR DYSTONIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETREATMENT; REVIEW; RISK FACTOR; SPASMODIC DYSPHONIA; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DYSTONIC DISORDERS; HUMANS; LONGITUDINAL STUDIES; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84870296423     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-012-9314-y     Document Type: Review

References (84)

1. Abbruzzese G, Berardelli A (2006) Neurophysiological effects of botulinum toxin type A. Neurotoxic Res 9:109-114
2. Albanese A (2009) Discussion of unique properties of botulinum toxins. Toxicon 54:702-708
3. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Solé J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5-18
4. Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19:S68-S84
5. Atassi MZ, Oshima M (1999) Structure, activity and immune recognition of botulinum neurotoxins. Crit Rev Immunol 19:219-260
6. Ben-Shlomo Y, Camfield L, Warner T, On behalf of the ESDE Collaborative Group (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608-614
7. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotoxic Res 15:224-231
8. Berman B, Seeberger L, Kumar R (2005) Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 20:233-237
9. Blitzer A (2010) Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 17:28-30
10. Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435-1441
11. Borodic G, Johnson E, Goodnough M, Schantz E (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26-29
12. Brainin M, Barnes M, Baron J-C, Gilhus NE, Hughes R, Selmaj K, Waldemar G (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 11:577-581
13. Brans JWM, Lindeboom R, Aramideh M, Speelman JD (1998) Longterm effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 50:1461-1463
14. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J (2005) Longitudinal assessment of the dose consistency of botulinum toxin type A (Botox) for cervical dystonia. Adv Ther 22:49-55
15. Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6:S146-S168
16. Brin M, Lew M, Adler C et al (1999) Safety and efficacy of Neurobloc (botulinum toxin type B) in type A resistant cervical dystonia. Neurology 53(7):1431-1438
17. Brin MF, Aoki KR, Dressler D (2004) Pharmacology of botulinum toxin therapy. In: Brin MF, Comella C (eds) Dystonia: etiology, clinical features, and treatment. Lippincott Williams & Wilkins, Philadelphia, pp 93-112
18. Brin MF, Comella CL, Jankovic J (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353-1360
19. Byrnes ML, Thickbroom GW, Wilson SA et al (1998) The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 121:977-988
20. Calace P, Cortese G, Piscopo R et al (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophtalmol 13:331-336
21. Caleo M, Antonucci F, Restani L, Mazzocchio R (2009) A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 109:15-24
22. Camargo CH, Teive HA, Becker N, Munhoz RP, Werneck LC (2011) Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr 69:745-750
23. Ceballos-Baumann AO, Sheean G, Passingham RE, Mardsen CD, Brooks DJ (1997) Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain 120:571-582
24. Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6:119-126
25. Chapman MA, Barron R, Tanis DC et al (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29(7):1325-1337
26. Cillino S, Raimondi G, Gue'pratte N et al (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye 24:600-607
27. Colosimo C, Berardelli A (2011) Clinical phenomenology of dystonia. In: Brotchie J, Bezard E, Jenner P (eds) International Review of Neurobiology, vol 98. pp 509-524
28. Colosimo C, Tiple D, Berardelli A (2009) Treatment of blepharospasm. In: Truong D, Hallett M, Dressler D (eds) Manual of Botulinum toxin therapy. Cambridge University Press, Cambridge, pp 49-53
29. Colosimo C, Suppa A, Fabbrini G, Bologna M, Berardelli A (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15-21
30. CurràA, Berardelli A (2009) Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72:1095-1099
31. Damrose FJ, Goldman NS, Groessl EJ, Orloff LA (2004) The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 18:415-422
32. Defazio G, Abbruzzese G, Girlanda P et al (2002) Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59:418-420
33. Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34-38
34. Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc/Neurobloc. Eur J Neurol 13:11-15
35. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody induced botulinum-toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118-121
36. Dressler D, Bigalke H, Beneche R (2003) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 250:967-969
37. Dutton JJ (1996) Botulinum-A toxin in the treatment of craniocervical muscle spasms: short-and long-term, local and systemic effects. Surv Ophthalmol 41:51-65
38. Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum toxin A in the treatment of blepharospasm. Ophtalmology 95:1529-1534
39. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C (2004) Different types of botulinum toxin in humans. Mov Disord 19:S53-S59
40. Engstrom PF, Arnoult JB, Mazow ML et al (1987) Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophtalmology 17:971-975
41. Fabbrini G, Berardelli I, Moretti G et al (2010) Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 25:459-465
42. Filippi GM, Errico P, Santarelli R et al (1993) Botulinum A toxin effects o rat jaw muscle spindles. Acta Otolaryngol 113:400-404
43. Garcia Ruiz PJ, Martinez Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055-1057
44. Giglio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A (2000) Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48:20-26
45. Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasmand hemifacial spasm. Can J Neurol Sci 37:631-636
46. Grafe S, Hanschmann A (2010) Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis. Neurology 74(9 Suppl 2):A88
47. Grandas F, Elston J, Quinn N, Marsden CD (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767-772
48. Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213-217
49. Gudex CM, Hawthorne MR, Butler AG, Duffey P (1998) Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 13:941-946
50. Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93-108
51. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19:303-308
52. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J (2001) Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193-199
53. Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL (2007) Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 116:891-896
54. Hsiung GYR, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various Movement Disorders over a 10-year period. Mov Disord 17:1288-1293
55. Jankovic J (2004a) Treatment of cervical dystonia with botulinum toxin. Mov Disord 19:S109-S115
56. Jankovic J (2004b) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75:951b-957b
57. Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371-376
58. Jankovic J, Schwartz K (1995) Resistance and immunoresistance to botulinum toxin injections. Neurology 45:1743-1746
59. Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186-1188
60. Kraft SP, Lang AE (1988) Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ 139:837-844
61. Lowenstein DH, Aminoff MJ (1988) The clinical course of spasmodic torticollis. Neurology 38:530-532
62. Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER (2010) Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 16:8-11
63. Mejia NI, Young KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 20:592-597
64. Modugno N, Priori A, Berardelli A et al (1998) Botulium toxin restores presynaptic inhibition of group la afferents in patients with essential tremor. Muscle Nerve 21:1701-1705
65. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463-466
66. Müller J, Kemmler G, Wissel J et al (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842-846
67. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981-990
68. Paniello RC, Barlow J, Serna JS (2008) Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results. Laryngoscope 118:564-568
69. Papapetropoulos S, Singer C (2007) Botulinum toxin in movement disorders. Semin Neurol 27:183-194
70. Priori A, Berardelli A, Mercuri B, Manfredi M (1995) Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 118:801-807
71. Reimer J, Gilg K, Karow A, Esser J, Franke GH (2005) Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111:64-70
72. Rosales RL, Arimura K, Takenaga S et al (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin injection. Muscle Nerve 19:488-496
73. Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C (2001) Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 39:27-41
74. Sampaio C, Costa J, Ferreira JJ (2004) Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19:S129-S136
75. Scott AB, Kennedy RA, Stubbs HHA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103:347-350
76. Simpson DM, Blitzer A, Brashear A (2008) Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1699-1706
77. Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163-170
78. Skogseid IM, Malt UF, Roislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129-1137
79. Tan EK, Jankovic J (1999) Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53:2102-2107
80. Tiple D, Strano S, Colosimo C et al (2008) Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A. J Neurol 255:843-847
81. Trompetto C, Currà A, Buccolieri A, Suppa A, Abbruzzese G, Berardelli A (2006) Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord 21:777-782
82. Truong D, Brodsky M, Lew M et al (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316-323
83. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC (1995) Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18:720-729
84. Vitek JL (2002) Pathophysiology of dystonia: a neuronal model. Mov Disord 17:S49-S62